CALA Calithera Biosciences Inc.

10.25
+0.12  (1%)
Previous Close 10.13
Open 10.30
Price To book 2.30
Market Cap 363635980
Shares 35,476,681
Volume 166,506
Short Ratio 6.77
Av. Daily Volume 696,774

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171172442
  2. 8-K - Current report 171172269
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171108064
  4. 8-K - Current report 171096161
  5. 8-K - Current report 171055440

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2017.
CB-839 with paclitaxel
Triple negative breast cancer
Phase 2 initiation announced August 7, 2017.
CB-839 + AFINITOR (everolimus)‎
Clear cell renal cell carcinoma
Phase 1 oral presentation at ASCO, June 5, 2017.
CX-1158-101
Solid tumors - cancer
Phase 1/2 enrollment commenced August 2016. Oral presentation November 11, 2017 at 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer

Latest News

  1. Calithera Sell-Off Unwarranted as Investors Ignore Positive Signal in Upcoming Breast Cancer Data
  2. Calithera Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : CALA-US : November 8, 2017
  3. Is Calithera Biosciences Inc (CALA) Undervalued?
  4. Initial Results from Phase 2 Study of CB-839 in Combination with Opdivo® (nivolumab) to be Presented at the Society for Immunotherapy of Cancer Meeting
  5. Calithera Biosciences, Q3 Analysis, Analysts Target and Clinical Trials Review
  6. Calithera reports 3Q loss
  7. Calithera Biosciences Reports Third Quarter 2017 Financial Results and Recent Highlights
  8. Zacks.com highlights: Amtech Systems, Grupo Financiero Galicia S.A., Calithera Biosciences, RedHill Biopharma and Protagonist Therapeutics
  9. 5 Stocks in Focus on New Analyst Coverage
  10. Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 24, 2017
  11. Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda
  12. Surging Earnings Estimates Signal Good News for Calithera Biosciences (CALA)
  13. Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences
  14. Calithera Biosciences, Inc. – Value Analysis (NASDAQ:CALA) : October 5, 2017
  15. Calithera Biosciences Announces Appointment of Sumita Ray as General Counsel
  16. Calithera Biosciences Appoints Blake Wise to Board of Directors
  17. Calithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable
  18. Calithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
  19. Calithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : September 12, 2017

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171172442
  2. 8-K - Current report 171172269
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171108064
  4. 8-K - Current report 171096161
  5. 8-K - Current report 171055440
  6. EFFECT - Notice of Effectiveness 171042073
  7. 424B5 - Prospectus [Rule 424(b)(5)] 171041287
  8. CORRESP [Cover] - Correspondence
  9. UPLOAD [Cover] - SEC-generated letter
  10. S-3 - Registration statement under Securities Act of 1933 171015257